Compound: MK-2206
SMILES: O=c1n2c(c3c(nc(-c4ccc(C5(N)CCC5)cc4)c(c3)-c6ccccc6)cc2)n[nH]1
InChIKey: ULDXWLCXEDXJGE-UHFFFAOYSA-N
Synonyms: MK-2206, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one, MK 2206, MK2206, 51HZG6MP1K, DTXCID0028874, DTXSID3048948, CHEBI:67271, 1032349-77-1, 1,2,4-Triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl(1,2,4)triazolo(3,4-f)(1,6)naphthyridin-3(2H)-one, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-2H-(1,2,4)triazolo(3,4-f)(1,6)naphthyridin-3-one, RefChem:553219, 4HA45S22ZZ, 1032349-93-1, MK-2206 free base, MK-2206 (free base), CHEMBL1079175, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, NCGC00186465-01, 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, UNII-51HZG6MP1K, 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-ol, CAS-1032350-13-2, 8-(4-(1-AMINOCYCLOBUTYL)PHENYL)-9-PHENYL-1,2,4-TRIAZOLO(3,4-F)(1,6)NAPHTHYRIDIN-3(2H)-ONE, SCHEMBL530721, MK2206 2HCl, GTPL7945, orb1942981, SCHEMBL2027678, MK-2206 2HCl?, ULDXWLCXEDXJGE-UHFFFAOYSA-N, DTXSID801365116, Tox21_113368, BDBM50313650, NSC756656, NSC800794, NSC839864, AKOS032945686, Tox21_113368_1, NSC-756656, NSC-800794, NSC-839864, SB16805, SDCCGSBI-0654336.P001, NCGC00186465-02, NCGC00186465-03, NCGC00186465-04, NCGC00186465-08, HY-10357, DB-058959, CS-0002565, F86411, MK2206;MK 2206;MK-2206 dihydrochloride, cas:1032350-13-2;MK 2206, BRD-K68065987-300-02-6, BRD-K68065987-300-09-1, Q25100065, 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridin-3(2H)-one
Theoretical properties:
molecular_formula: C25H21N5O
molecular_weight: 407.5 g/mol
exact_mass: 407.17461031 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 4
rotatable_bond_count: 3
heavy_atom_count: 31
topological_polar_surface_area: 83.6 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: MK-2206 is an organic heterotricyclic compound that is [1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one substituted by 4-(1-aminocyclobutyl)phenyl and phenyl groups at positions 8 and 9, respectively. It is an allosteric Akt inhibitor. It has a role as an autophagy inducer, an antineoplastic agent, an EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor and an apoptosis inducer. It is a member of cyclobutanes, a member of benzenes, an organic heterotricyclic compound and a primary amino compound.
chebi: An organic heterotricyclic compound that is [1,2,4]triazolo[3,4-<em>f</em>][1,6]naphthyridin-3(2<em>H</em>)-one substituted by 4-(1-aminocyclobutyl)phenyl and phenyl groups at positions 8 and 9, respectively. It is an allosteric Akt inhibitor.
chembl: MK-2206 is a small molecule listed in the ChEMBL database and has reached clinical trial phase 2.0.
wikipedia: MK-2206 is a drug candidate being investigated to help treat cancer. Its chemical formula is C25H21N5O. It acts as an allosteric AKT inhibitor.
It is a highly selective inhibitor of pan-Akt, namely, of all three Akt isoforms Akt1, Akt2, and Akt3.
It is intended to be used with other cancer therapies that advanced tumours may become resistant to.